YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This article first appeared on GuruFocus. Release Date: September 22, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PureTech Health PLC ended H1 2026 with $220 mil…
* PureTech Health plc press release [https://seekingalpha.com/pr/20214107-puretech-health-plc-half-year-report] (OTC:PTCHF [https://seekingalpha.com/symbol/PTCHF]): 1H ~$320M PureTech level cash, cash equivalents and short-term investments…
Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea BOSTON, August 12, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to ch…
* Clinical-stage biotherapeutics company PureTech Health (NASDAQ:PRTC [https://seekingalpha.com/symbol/PRTC]) said that [https://seekingalpha.com/pr/20167285-puretech-announces-leadership-transition] Bharatt Chowrira, PhD, JD, has stepped…
BOSTON, January 03, 2024--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today a…
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Tr…
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust balance sheet position with estimated Consolid…
LYT-200 demonstrates favorable safety profile and anti-tumor activity in combination with anti-PD-1 agent, tislelizumab Three out of four patients treated so far with head and neck cancers experienced disease control, with one complete res…
Prescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The application is supported by positive data f…
Results demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.5…
Orally administered LYT-300 achieved a statistically significant (p=0.0001) reduction in the stress hormone response, as measured by salivary cortisol, compared to placebo This proof-of-concept trial demonstrating a reduction in the physio…
Company summarizes third quarter progress across its Wholly Owned Pipeline and Founded Entities BOSTON, October 17, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biothe…
LYT-100 demonstrated ~50% improvement versus pirfenidone in key adverse events at a comparable exposure level, which may lead to better patient compliance and improved treatment outcomes in IPF LYT-100 also demonstrated favorable tolerabil…
VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis Vedanta’s pipeline also includes VE303, its Phase 3 ready therapeutic candidate designed for the prevention of recur…
Founded Entity Karuna Therapeutics submits New Drug Application to U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia If approved, KarXT will be the first new mechanism in over 50 years for patients living with…
BOSTON, September 27, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today…
BOSTON, August 22, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2023, on Tuesday, August 29, 2023. A presenta…
Planning underway for Phase 2 trial of LYT-300 in Fragile X-associated Tremor/Ataxia Syndrome LYT-300 is also being evaluated in a Phase 2a trial for anxiety disorders, and a Phase 2a in patients with postpartum depression is planned to in…
Results from a validated clinical model of anxiety in healthy volunteers anticipated by the end of 2023 Phase 2a clinical trial of LYT-300 in patients with postpartum depression planned to initiate in second half of 2023 LYT-300 is derived…
BOSTON, June 13, 2023--(BUSINESS WIRE)--The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech Health" or the "Company") was held at 11 a.m. EDT/4 p.m. BST on Tuesday, June 13, 2023. All of the resolutions p…
BOSTON, May 24, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today annou…
VE303 receives Fast Track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships be…
Attention improved in more than 80 percent of adults with ADHD, and over one-third of participants no longer exhibited an attention deficit following treatment Improvements in attention were nearly seven times larger than those seen in the…
Participants Allison Mead Talbot; Head of Communications & IR; PureTech Health plc Bharatt M. Chowrira; President, Secretary, Chief Business Finance & Operating Officer and Executive Director; PureTech Health plc Daphne Zohar; Founder, CEO…
Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in2Q 2023 Syndicate led by new investors AXA IM…
JAMA publication includes in-depth safety and efficacy results from Vedanta’s successful Phase 2 study of VE303 BOSTON, April 17, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinica…
BOSTON, April 13, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Friday, April 28, 2023, at 2:00 AM EDT/ 7:00 AM BST. The repor…
Royalty Pharma plc Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds PureTech retains its current equity s…
Royalty Pharma has acquiredan interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds. PureTech retains its current equity stake in Karuna in a…
BOSTON, March 01, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today ann…
Project to leverage vocal biomarkers for cognitive assessment of patients ages 55 and above in home environment BOSTON, February 27, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clin…
A placebo-controlled, Phase 2a, proof-of-concept, social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the end of 2023 An open-label, Phase 2a, proof-of-concept cli…
BOSTON, February 01, 2023--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today…
Rapid advancement of PureTech’s Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral…
Orally administered LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic effect.1 Allopregnanolone is a natural neurosteroid with proven efficacy that is currently only available as a 60-hour intr…
In this article, we discuss the 10 best immunology stocks to invest in. If you want to read about some more immunology stocks, go directly to 5 Best Immunology Stocks to Invest In. Immunology is the study of the immune system of higher org…